GlassScriptPhysician profile
Dana A Webb
NPI 1487662177
$982.85
in general payments reported to CMS, 2019-2025
13 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.41 · 2020: $60.82 · 2021: $57.21 · 2022: $64.33 · 2023: $191 · 2024: $213 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $225.77 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $157.65 | 2019-2025 | Tryptyr, Rocklatan, Hydrus Microstent |
| Abbvie INC. | $130.08 | 2023-2025 | Vuity, Lumigan |
| Oyster Point Pharma, INC. | $108.98 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $73.13 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.95 | 2019-2021 | |
| Dompe US, INC. | $48.72 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $45.94 | 2020-2023 | Acuvue |
| Thea Pharma INC. | $44.90 | 2025 | Iyuzeh |
| Glaukos Corporation | $27.63 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.71 | 2021 | |
| Amgen INC. | $17.22 | 2025 | Tepezza |
| Coopervision INC. | $15.17 | 2023 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.